China Gender-affirming Hormone Therapy Study
China Gender-affirming Hormone Therapy Study in Transgender Men and Women
Peking University Third Hospital
240 participants
Apr 16, 2022
OBSERVATIONAL
Conditions
Summary
Data about transgender medical care, especially the gender-affirming hormone therapy (GAHT) is extremely insufficient in China. Few evidence exists in the physical and psychological effects of the hormonal treatment in Chinese transgender population. CGAHT is designed to describe the social and mental condition of transgender people who are seeking for formal GAHT, and to investigate the physical and psychological effects of GAHT on this population in China.
Eligibility
Inclusion Criteria7
- Transgender men and women
- Meet criteria of Diagnostic and Statistical Manual of Mental Disorders (Fifth Edition) for gender dysphoria
- Aged between 18 to 40 years
- People desire to start the GAHT
- No previous history of gender-affirming interventions
- Having full ability to make informed consent
- Dextromanual
Exclusion Criteria13
- Disorders of sex development
- Who has fertility demand but have not made fertility preservation
- With contradictions of GAHT
- Comorbid diseases are not under control
- Alcohol or drug abuse
- Hormonal and chromosomal disorders
- History of gender affirming surgery
- Current psychiatric disorders
- History of brain trauma or neurological pathologies
- Current use of medications with psychotropic effects within two weeks (antipsychotic or antiepileptic agents, lithium, benzodiazepines or opioid analgesics)
- Claustrophobia
- Implanted metal and medical devices (pacemakers, ceramic teeth, etc.),
- Tattoos or eyebrow tattooing (heavy metal dye)
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Testosterone undecanoate
Estradiol and antiandrogens (Spironolactone or Cyproterone acetate)
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05318755